SCYNEXIS, Inc.

SCYNEXIS, Inc. is a biotechnology company headquartered in Jersey City, New Jersey, dedicated to developing innovative medicines for difficult-to-treat and drug-resistant infections and severe rare diseases. The company's mission is to positively impact the lives of patients facing limited therapeutic options and significant unmet medical needs.

SCYNEXIS's portfolio includes a focus on antifungal therapies and treatments for rare diseases. Its lead antifungal product, BREXAFEMME (ibrexafungerp tablets), approved by the U.S. FDA for vulvovaginal candidiasis (VVC) and recurrent VVC, has been licensed to GSK for commercialization and further development. The company is also advancing SCY-247, a second-generation fungerp, for the treatment and prevention of invasive fungal infections, and recently acquired PXL-770, a clinical-stage direct AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Recent corporate activities include a $40.0 million private placement and the transformative acquisition of PXL-770 in March 2026. SCYNEXIS also announced the dosing of the first participants in a Phase 1 trial for intravenous SCY-247 in February 2026, and the drug received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations in January 2026. David Angulo, M.D., serves as the President and Chief Executive Officer, having been appointed in January 2023. The company continues to strategically position itself in the biotechnology sector by focusing on its pipeline for severe rare diseases and life-threatening infections.